Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Profit After Tax (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Profit After Tax for 15 consecutive years, with -$10.6 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 1691.58% to -$10.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$23.9 million through Dec 2025, down 478.89% year-over-year, with the annual reading at -$13.6 million for FY2025, 8.32% down from the prior year.
  • Profit After Tax for Q4 2025 was -$10.6 million at Aytu Biopharma, down from $2.0 million in the prior quarter.
  • The five-year high for Profit After Tax was $4.0 million in Q1 2025, with the low at -$53.3 million in Q1 2022.
  • Average Profit After Tax over 5 years is -$9.5 million, with a median of -$6.7 million recorded in 2022.
  • The sharpest move saw Profit After Tax skyrocketed 402.27% in 2024, then plummeted 1691.58% in 2025.
  • Over 5 years, Profit After Tax stood at -$11.5 million in 2021, then surged by 42.04% to -$6.7 million in 2022, then soared by 96.71% to -$220000.0 in 2023, then surged by 402.27% to $665000.0 in 2024, then tumbled by 1691.58% to -$10.6 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$10.6 million, $2.0 million, and -$19.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.